Improving Patient Adherence and Quality
of Life in Multiple Sclerosis: Strategies for Managing Adverse
Events Associated with New and Emerging Therapies
A continuing medical education
activity provided by NAMCP and AAMCN
Managing Clinical and Cost Outcomes in Multiple Sclerosis: Utilizing
Data to Make
Informed Decisions in Managed Care is a three-part webinar series
This is Part 3 of the series focusing on Improving patient adherence
and quality of life
This activity is an archive from the webinar held December 1, 2020
This activity is valid from January 1, 2021 to January 1, 2023
Instructions for CME/NCPD: Complete the pre-test, listen to the
audio and view the slides, complete the post test, complete the
evaluation form and hit submit. You will be asked to enter your name
and email address on the pre-test, evaluation and post-test. If you
close your internet browser without completing the post test, you
will have ONE more opportunity to complete. A score of 70% must be
achieved on the post test to receive continuing education credits.
If you do not pass the post test after two attempts, you will not be
eligible to try again. Once you complete the evaluation form and
score 70% or higher on your post test, you will automatically be
given your certificate.
To print or save your certificate, you will need to click on the
“download” button and either print or save.
This activity is intended for healthcare professionals practicing in
managed care environments.
This activity is supported by
educational grants from
Biogen, Novartis and Sanofi Genzyme
Multiple Sclerosis (MS) is a chronic progressive disease. It is the
most common neurological cause of disability among young adults,
with a prevalence of approximately one million cases throughout the
United States. Although there is still no cure for MS, many advances
in MS treatment have arrived in recent years, allowing patients to
manage these symptoms and improve their quality of life. Effective
and timely treatment of MS can greatly improve the quality of life
in MS patients. With the advancement and complexity of different
treatment options, including therapies that have recently become
available, managed care professionals are being challenged to make
informed decisions in their organizations and provide the correct
treatment options that are available to patients.
Upon completion of this
activity, participants will be able to:
Examine challenges to patient
adherence, dosing and quality of life in multiple sclerosis and
adverse event management
Review strategies to monitor and
manage adverse events associated with newer therapies, including
S1P therapies and anti-CD-20 monoclonal antibodies, in MS in
order to improve patient adherence and quality of life
Explore the role of subcutaneous
administration methods in new and emerging therapies in MS
Identify and develop strategies to
overcome potential barriers that affect timely access of MS
disease-modifying therapies (DMTs) for patients through managed
||Fred D. Lublin, MD, FAAN,
Saunders Family Professor of Neurology
Director, The Corinne Goldsmith Dickinson Center for
Icahn School of Medicine at Mount Sinai
serves as a consultant for Biogen; EMD Serono; Novartis;
Actelion/Janssen; Sanofi/Genzyme; Roche/Genentech;
MedImmune/ Viela Bio; Receptos/Celgene/BMS; TG
Therapeutics; Medday; Atara Biotherapeutics; Innate
Immunotherapeutics; Apitope; Orion Biotechnology;
Brainstorm Cell Therapeutics; Jazz Pharmaceuticals; GW
Pharma; Mylan; Immunic; Population Council; Avotres;
Neurogene. He has received grants/research support from
Novartis; Actelion; Biogen; Sanofi, NMSS, NIH;
Brainstorm Cell Therapeutics. His presentation has been
peer reviewed for any bias.
MD has no real or perceived financial relationships to
Jeremy Williams has no real or perceived financial
relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no real or perceived
financial relationships to disclose.
NAMCP and/or the presenter
has copyright or has received permissions for use of
materials provided in this activity.
Accreditation & Designation
This activity has been planned and implemented in accordance with
the accreditation requirements and policies of the Accreditation
Council for Continuing Medical Education (ACCME) through the joint
providership of the National Association of Managed Care Physicians
(NAMCP) and American Association of Managed Care Nurses (AAMCN). The
National Association of Managed Care Physicians is accredited by the
ACCME to provide continuing medical education for physicians.
NAMCP designates this enduring material for a maximum of 1 AMA
PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their
participation in the activity.
The American Association of Managed Care Nurses is accredited as a
provider of nursing continuing professional development by the
American Nurses Credentialing Center's Commission on Accreditation.
Nurses who complete this activity and achieve a passing score will
receive 1 hour in nursing continuing professional development.
This activity has been approved by the American Board of Managed
Care Nursing for 1.0 contact hours toward CMCN recertification
This activity is supported by educational grants from
Biogen, Novartis and Sanofi Genzyme
NAMCP and/or this website does not
provide medical advice, diagnosis or treatment. NAMCP does not
endorse or imply endorsement of the content on any linked website.
This website is to be used as an informational resource. With any
health related concern, consult with your physician or healthcare
Click Here To Continue